Cambridge Financial Group Inc. Has $5.26 Million Stake in Humana Inc. (NYSE:HUM)

Cambridge Financial Group Inc. boosted its holdings in Humana Inc. (NYSE:HUM) by 4.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,488 shares of the insurance provider’s stock after buying an additional 493 shares during the period. Humana makes up about 2.6% of Cambridge Financial Group Inc.’s investment portfolio, making the stock its 27th biggest position. Cambridge Financial Group Inc.’s holdings in Humana were worth $5,259,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rakuten Securities Inc. acquired a new stake in shares of Humana during the fourth quarter worth $25,000. Gradient Investments LLC increased its stake in shares of Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 40 shares during the last quarter. Cetera Trust Company N.A bought a new position in Humana during the 4th quarter worth approximately $28,000. Nvwm LLC increased its stake in Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after purchasing an additional 25 shares in the last quarter. Finally, Operose Advisors LLC bought a new stake in Humana in the third quarter valued at approximately $56,000. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

NYSE:HUM traded down $0.44 on Friday, hitting $320.54. The company’s stock had a trading volume of 1,802,675 shares, compared to its average volume of 1,607,966. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. Humana Inc. has a one year low of $298.61 and a one year high of $541.21. The stock has a fifty day moving average of $324.12 and a two-hundred day moving average of $387.61. The firm has a market capitalization of $38.63 billion, a P/E ratio of 19.96, a price-to-earnings-growth ratio of 1.86 and a beta of 0.49.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter in the prior year, the business earned $9.38 EPS. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. Research analysts predict that Humana Inc. will post 16.18 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.10%. Humana’s dividend payout ratio (DPR) is currently 22.04%.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research analyst reports. Truist Financial reaffirmed a “hold” rating and set a $550.00 price objective on shares of Humana in a research note on Friday, January 19th. The Goldman Sachs Group cut their price objective on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. Bank of America reiterated a “neutral” rating and set a $342.00 target price (down previously from $470.00) on shares of Humana in a report on Tuesday, April 2nd. Barclays cut their price target on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 2nd. Finally, Mizuho decreased their price objective on Humana from $550.00 to $400.00 and set a “buy” rating for the company in a report on Friday, January 26th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $424.50.

Insider Buying and Selling at Humana

In other news, Director Jorge S. Mesquita bought 545 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.